Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

Phase 3

Terminated

Conditions: Asthma

Interventions: Drug: QAW039 150 mg once daily
Drug: QAW039 450 mg once daily
Drug: Placebo once daily

First Posted Date: 2018-08-14

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 604

Registration Number: NCT03629249

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

Phase 3

Terminated

Conditions: Non-Small-Cell Lung

Interventions: Drug: Canakinumab
Drug: Docetaxel
Other: Placebo

First Posted Date: 2018-08-13

Last Posted Date: 2023-08-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 245

Registration Number: NCT03626545

Locations: 🇺🇸
University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States
🇺🇸
Montefiore Medical Center Albert Einstein College of Med, Bronx, New York, United States
🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States

and more 4 locations

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

Phase 3

Completed

Conditions: Multiple Sclerosis
Relapsing Multiple Sclerosis
Advancing Multiple Sclerosis

Interventions: Drug: Siponimod

First Posted Date: 2018-08-09

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 185

Registration Number: NCT03623243

Locations: 🇵🇷
Novartis Investigative Site, Guaynabo, Puerto Rico
🇺🇸
MS & Neuromuscular Center of Excellence, Clearwater, Florida, United States
🇺🇸
Alabama Neurology Associates, Homewood, Alabama, United States

and more 1 locations

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.

Phase 2

Completed

Conditions: Lupus Nephritis

Interventions: Drug: CFZ533
Drug: Placebo

First Posted Date: 2018-08-01

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 57

Registration Number: NCT03610516

Locations: 🇹🇷
Novartis Investigative Site, Kocaeli, Turkey

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

Phase 2

Completed

Conditions: Non-Hodgkin Lymphoma

Interventions: Biological: Tisagenlecleucel
Drug: lymphodepleting chemotherapy
Drug: Bridging Therapy

First Posted Date: 2018-08-01

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT03610724

Locations: 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Johns Hopkins Oncology Center ORA, Baltimore, Maryland, United States
🇺🇸
Cinn Children Hosp Medical Center, Cincinnati, Ohio, United States

and more 8 locations

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Asciminib

First Posted Date: 2018-07-30

Last Posted Date: 2021-10-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT03605277

Locations: 🇩🇪
Novartis Investigative Site, Berlin, Germany

CTL019 Out of Specification MAP for ALL or DLBCL Patients

Conditions: Diffuse Large B-cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukemia (ALL)

First Posted Date: 2018-07-26

Last Posted Date: 2024-10-28

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03601442

Locations: 🇺🇸
Banner MDACC, Gilbert, Arizona, United States
🇺🇸
University of Arizona Cancer Center, Phoenix, Arizona, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States

and more 140 locations

Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.

Phase 3

Withdrawn

Conditions: Liver Transplantation

Interventions: Drug: TAC withdrawal
Drug: Everolimus with reduced TAC

First Posted Date: 2018-07-24

Last Posted Date: 2018-07-24

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03596970

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

Phase 2

Recruiting

Conditions: FLT3-mutated Acute Myeloid Leukemia

Interventions: Drug: Midostaurin
Drug: Fludarabine
Drug: Cytarabine
Drug: Daunorubicin or idarubicin
Drug: Mitoxantrone
Drug: Etoposide

First Posted Date: 2018-07-19

Last Posted Date: 2024-04-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 23

Registration Number: NCT03591510

Locations: 🇹🇷
Novartis Investigative Site, Istanbul, Turkey

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Placebo 2 mL auto-injector
Drug: Placebo 1 mL prefilled syringe
Drug: Secukinumab 2 mL auto-injector
Drug: Secukinumab 1 mL prefilled syringe

First Posted Date: 2018-07-18

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 122

Registration Number: NCT03589885

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy